Radiotherapy for Meningioma
For WHO grade I meningiomas, stereotactic radiosurgery (SRS) at 12-15 Gy in a single fraction is recommended as primary treatment for surgically inaccessible tumors or as adjuvant/salvage therapy after incomplete resection, while fractionated radiotherapy at 45-54 Gy is reserved for larger lesions; WHO grade II meningiomas should receive 45-54 Gy fractionated radiotherapy after incomplete resection (with early adjuvant therapy increasingly favored even after gross total resection given superior progression-free survival), and WHO grade III meningiomas require aggressive treatment with 54-60 Gy in 1.8-2.0 Gy fractions to the tumor bed plus margin regardless of resection extent. 1
WHO Grade I (Benign) Meningiomas
Indications for Radiotherapy
- Primary treatment: Surgically inaccessible tumors, particularly skull base locations where resection carries significant morbidity risk 2
- Adjuvant therapy: After subtotal resection when complete removal is not feasible
- Salvage therapy: For recurrent disease after initial surgery 2
Radiation Doses and Techniques
Stereotactic Radiosurgery (SRS)
- Dose: 12-15 Gy delivered in a single fraction 2, 1
- Tumor size: Best suited for small tumors, typically <3 cm diameter 3
- Outcomes: 10-year local control rates of 71-100%, with progression-free survival of 55-97% 2
- Toxicity: Generally low complication rates 2
Fractionated Radiotherapy
- Dose: 45-54 Gy in 1.8-2.0 Gy fractions 1
- Indications: Larger tumors (>3 cm), tumors adjacent to critical structures, or when SRS is not feasible 3
- Technique: Stereotactic radiotherapy (SRT) delivered over 5-6 weeks 2
Evidence Quality
The ISRS guideline emphasizes that while level I and II evidence is lacking, the large body of level III studies provides sufficient evidence to recommend SRS as an effective treatment option (recommendation level II) for grade I meningiomas 2. This represents the highest quality guideline evidence available for benign meningiomas.
WHO Grade II (Atypical) Meningiomas
Indications for Radiotherapy
The timing of radiotherapy for grade II meningiomas remains the most controversial aspect of meningioma management, but recent evidence strongly favors early intervention.
Early Adjuvant Radiotherapy (Recommended Approach)
- After incomplete resection: Universally recommended 1, 4
- After gross total resection: Increasingly supported by recent data showing dramatic differences in progression-free survival 5
Critical Evidence on Timing
A 2026 multicenter study with >7 years follow-up demonstrated striking differences in outcomes based on RT timing 5:
- Early RT: 10-year PFS of 89.3% after GTR
- Late RT (at progression): 10-year PFS of only 18.8% after GTR
- Tumor-related mortality: Sixfold higher with late RT (16.7% vs 2.7%, p=0.011)
This represents the most recent and compelling evidence that early adjuvant radiotherapy provides durable progression-free survival benefit even after complete resection, though it does not translate to overall survival advantage 5.
Radiation Doses
Risk Stratification
Consider molecular markers when available to guide treatment decisions 7:
- Mitotic count and Ki-67 index independently predict early and long-term PFS
- DNA methylation profiles and copy number variations improve prognostic accuracy beyond WHO grading alone
WHO Grade III (Anaplastic/Malignant) Meningiomas
Indications for Radiotherapy
Adjuvant radiotherapy is mandatory regardless of extent of resection 1, 4. The aggressive nature of these tumors necessitates combined modality treatment.
Radiation Doses
- Dose: 54-60 Gy in 1.8-2.0 Gy fractions 1
- Target volume: Tumor bed plus gross tumor with 2-3 cm margin 1
- SRS for small recurrent tumors: 18-22 Gy margin dose 6
Outcomes
- Median 5-year PFS: Only 13% for grade III tumors treated with radiosurgery 6
- These poor outcomes underscore the need for aggressive upfront treatment and consideration of clinical trials
Technical Considerations
Target Volume Definition
- Include enhancing tumor on T1-weighted MRI with contrast
- Consider inclusion of dural tail (controversial but often included)
- Hyperostotic bone inclusion remains debated 8
- Use 2-3 cm margin for grade III tumors 1
Emerging Technologies
DOTATATE-PET imaging is increasingly valuable for:
- More accurate delineation of tumor extent, particularly for WHO grade II and III tumors 9, 10
- Assessment of response to radiotherapy 9
- Guiding target volume definition for radiation planning 10
Common Pitfalls to Avoid
Delaying RT in grade II meningiomas after GTR: Recent evidence shows this approach results in dramatically worse PFS and increased tumor-related mortality 5
Undertreating grade III meningiomas: These require aggressive combined modality treatment regardless of surgical outcome
Using SRS for large tumors: Limit SRS to tumors <3 cm; use fractionated RT for larger lesions 3
Inadequate follow-up: Even completely resected benign meningiomas can recur up to 25 years later, necessitating lifelong surveillance 11
Ignoring molecular markers: When available, DNA methylation profiles and copy number variations provide superior prognostic information and should guide treatment intensity 7
Algorithm for Treatment Decision-Making
Step 1: Determine WHO Grade
- Grade I → Consider observation vs RT based on resection extent and location
- Grade II → Strong consideration for early adjuvant RT even after GTR
- Grade III → Mandatory adjuvant RT regardless of resection extent
Step 2: Assess Tumor Characteristics
- Size <3 cm + accessible location → SRS option for grade I
- Size >3 cm or near critical structures → Fractionated RT
- Skull base location → SRS preferred for grade I if <3 cm
Step 3: Apply Appropriate Dose
- Grade I: 12-15 Gy (SRS) or 45-54 Gy (fractionated)
- Grade II: 45-54 Gy (fractionated) or 16-20 Gy (SRS for small tumors)
- Grade III: 54-60 Gy (fractionated) or 18-22 Gy (SRS for small recurrent disease)
Step 4: Consider Molecular Profiling
- If available, use integrated molecular-morphologic classification to refine risk stratification and treatment intensity 7